Aspects of the pathogenesis of anemia in cancer patients

Abstract

Anemia is considered one of the manifistations of many neoplasms affecting the overall survival and reducing the quality of life of patients. The prevalence of anemia varies from 20 to 90% depending on the nosology, the stage of the disease, antitumor treatment. The pathogenesis of anemia in cancer patients is complex. Among pathogene­tic factors, such factors are distinguished as tumor infiltration of the bone marrow by malignant cells, inhibition of erythroid growth by cytokines of inflammation, decreased sensitivity of receptors to erythropoietin and its production, increased levels of hepcidin, defects of nutrition, increased deposition and sequestration of blood cells in the spleen, excessive bone fibrosis, hemorrhagic syndrome, antitumor therapy. The article presents the pathogenesis of anemia in oncological disease with a detailed description of the suppressive effect on hematopoiesis of a number of proinflammatory cytokines (interleukin-1β, interleukin-6, tumor necrosis factor-α, interferon-γ) produced by cells of the immune system. The mechanism of influence of cytokines on erythropoiesis, synthesis of erythropoietin as well as on the enhancement of hepcidin production in the body is presented in detail. The article also describes the mechanism of impairment of iron kinetics in the body in patients with cancer and subsequent development of functional deficiency. This review of the literature contains up-to-date information about the factors involved in the pathogenesis of anemia in cancer patients, understanding of which will allow the clinical physician to choose a rational way of pathogenetic or substitution correction of anemic syndrome, taking into account the personalized approach to treatment and prevention, especially in patients receiving surgical, chemotherapy, radiation treatment.

Keywords

anemia / erythropoietin / hepcidin / iron / lymphoproliferative disease / cancer patients / cancer / cytokines / erythropoietin / interleukin-1β / interleukin-6 / tumor necrosis factor-α / interferon-γ

References

[1] Romanenko N.A., Chechetkin A.V., Zhiguleva L.Yu. et al. Correction of anemia and evaluation of efficacy of red blood cell transfusion in patients with oncohematological di­seases. Klinicheskaya onkogematolo­giya. 2018; 11 (3): 265–272. (In Russ.)

[2] Романенко Н.А., Чечёткин А.В., Жигулева Л.Ю. и др. Коррекция анемии и оценка эффективности трансфузий эритроцитов у пациентов с онкогематологическими заболеваниями. Клин. онкогематол. 2018; 11 (3): 265–272. DOI: 10.21320/2500-2139-2018-11-3-265-278.

[3] Sakhin V.T., Madzhanova E.R., Kryukov E.V. et al. Pathogenetic pathogenetic characteristics of anemia in patients with solid tumors. Klinicheskaya onkogematolo­giya. 2017; 10 (4): 514–518. (In Russ.)

[4] Сахин В.Т., Маджанова Е.Р., Крюков Е.В. и др. Патогенетические особенности анемии у больных с солидными опухолями. Клин. онкогематол. 2017; 10 (4): 514–518. DOI: 10.21320/2500-2139-2017-10-4-514-518.

[5] Liu X., Qiu H., Huang Y. et al. Impact of preoperative anemia on outcomes in patients undergoing curative resection for gastric cancer: a single-institution retrospective analysis of 2163 Chinese patients. Cancer Med. 2018; 7 (2): 360–369. DOI: 10.1002/cam4.1309.

[6] Santos F.P., Alvarado Y., Kantarjian H. et al. Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. Cancer. 2011; 117 (5): 982–991. DOI: 10.1002/cncr.25533.

[7] Douros A., Jobski K., Kollhorst B. et al. Risk of venous thromboembolism in cancer patients treated with epoetins or blood transfusions. J. Clin. Pharmacol. 2016; 82 (3): 839–848. DOI: 10.1111/bcp.13019.

[8] Schrijvers D., De Samblanx H., Roila F. Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann. Oncol. 2010; 21 (5): 244–247. DOI: 10.1093/annonc/mdq202.

[9] Romanenko N.A., Abdulkadyrov K.M. Patogenetic correction of anemia with erythropoiesis-sti­mulating agents in lymphoproliferative disorders (literature review). Onkogematologiya. 2011; (3): 39–49. (In Russ.)

[10] Романенко Н.А., Абдулкадыров К.М. Патогенетическая коррекция анемии эритропоэзстимулирующими препаратами у больных лимфопролиферативными заболеваниями (обзор литературы). Онкогематология. 2011; (3): 39–49. DOI: 10.17650/1818-8346-2011-6-3-39-49.

[11] Birgegard G., Samuelsson J., Ahlstrand E. et al. Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group. Eur. J. Haematol. 2019; 102 (3): 235–240. DOI: 10.1111/ejh.13198.

[12] Steurer M., Wagner H., Gastel G. Prevalence and management of anaemia in haematologic cancer patients receiving cyclic nonplatinum chemotherapy: results of a prospective national chart survey. Wien. Klin. Wochenschr. 2004; 116 (11–12): 367–372. DOI: 10.1007/BF03040915.

[13] Tefferi A., Lasho T.L., Jimma T. et al. One thousand patients with primary myelofibrosis: the mayo ­clinic experience. Mayo Clin. Proc. 2012; 87 (1): 25–33. DOI: 10.1016/­j.mayocp.2011.11.001.

[14] Truong P.T., Parhar T., Hart J. et al. Population-based analysis of the frequency of anemia and its ma­nagement before and during chemotherapy in patients with malignant lymphoma. Am. J. Clin. Oncol. 2010; 33 (5): 465–468. DOI: 10.1097/COC.0b013e3181b4b147.

[15] Yasmeen T., Ali J., Khan K., Siddiqui N. Frequency and causes of anemia in lymphoma patients. Pak. J. Med. Sci. 2019; 35 (1): 61–65. DOI: 10.12669/pjms.35.1.91.

[16] Baumeister P., Canis M., Reiter M. Preoperative anemia and perioperative blood transfusion in head and neck squamous cell carcinoma. PLoS One. 2018; 13 (10): e0205712. DOI: 10.1371/journal.pone.0205712.

[17] Baumeister P., Rauch J., Jacobi C. et al. Impact of comorbidity and anemia in patients with oropharyngeal cancer primarily treated with surgery in the human papillomavirus era. Head Neck. 2017; 39 (1): 7–16. DOI: 10.1002/hed.24528.

[18] Ceanga A.I., Ceanga M., Eveslage M. et al. Preope­rative anemia and extensive transfusion during stay-in-hospital are critical for patient`s mortality: A retrospective multicenter cohort study of oncological patients undergoing radical cystectomy. Transfus. Apher. Sci. 2018; 57 (6): 739–745. DOI: 10.1016/j.transci.2018.08.003.

[19] Bessmel’tsev S.S., Romanenko N.A. Anemiya pri opukholevykh zaboleva­niyakh sistemy krovi. Rukovodstvo dlya vrachey. (Anemia in tumor diseases of the blood system: hands. Guide for doctors.) Moscow: SIMK. 2017; 228 p. (In Russ.)

[20] Бессмельцев С.С., Романенко Н.А. Анемия при опухолевых заболеваниях системы крови. Руководство для врачей. М.: СИМК. 2017; 228 с.

[21] Chau J.K., Harris J.R., Seikaly H.R. Transfusion as a predictor of recurrence and survival in head and neck cancer surgery patients. J. Otolaryngol. Head Neck. Surg. 2010; 39 (5): 516–522. PMID: 20828514.

[22] Danan D., Smolkin M.E., Varhegyi N.E. et al. Impact of blood transfusions on patients with head and neck cancer undergoing free tissue transfer. Laryngoscope. 2015; 125 (1): 86–91. DOI: 10.1002/lary.24847.

[23] Russian clinical guidelines for the diagnosis and treatment of lymphoproliferative diseases. Ed. by I.V. Poddubnaya, V.G. Savchenko. Moscow: Buki Vedi. 2016; 324 p. (In Russ.)

[24] Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний. Под ред. И.В. Поддубной, В.Г. Савченко. М.: Буки Веди. 2016; 324 с. .

[25] Samuelsson J. Long-standing resolution of anemia in symptomatic low-grade non-Hodgkin's lymphoma patients treated with recombinant human erythropoietin as sole therapy. Med. Oncol. 2002; 19 (1): 69–72. DOI: 10.1385/MO:19:1:69.

[26] Nowrousian M.R. Recombinant human erythro­poietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours. Med. Oncol. 1998; 15 (1): 19–28. DOI: 10.1007/BF02821932.

[27] Haase V.H. Hypoxic regulation of erythropoiesis and iron metabolism. Am. J. Physiol. Renal. Physiol. 2010; 299 (1): 1–13. DOI: 10.1152/ajprenal.00174.2010.

[28] Liu Q., Davidoff O., Niss K., Haase V.H. Hypo­xia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. J. Clin. Invest. 2012; 122 (12): 4635–4644. DOI: 10.1172/JCI63924.

[29] Levchenkova O.S., Novikov V.E. Inductors of the regulatory factor to hypoxia adaptation. Rossiyskiy mediko-biologicheskiy vestnik im. akademika I.P. Pavlova. 2014; 22 (2): 134–143. (In Russ.)

[30] Левченкова О.С., Новиков В.Е. Индукторы регуляторного фактора адаптации к гипоксии. Рос. мед.-биол. вестн. им. акад. И.П. Павлова. 2014; 22 (2): 134–143. DOI: 10.17816/PAVLOVJ20142133-143.

[31] Pavlov A.D., Morshсрakova E.F., Rumyantsev A.G. Eritropoez, eritropoetin, zhelezo. Molekulyarnye i klinicheskie aspekty. (Erythropoiesis, erythropoietin, iron. Molecular and clinical aspects.) Moscow: GEOTAR-Media. 2011; 299 p. (In Russ.)

[32] Павлов А.Д., Морщакова Е.Ф., Румянцев А.Г. Эритропоэз, эритропоэтин, железо. Молекулярные и клинические аспекты. М.: ГЭОТАР-Медиа. 2011; 299 с.

[33] Romanenko N.A., Berkos M.V., Bessmel’tsev S.S. et al. Prognostic value of serum ery­thropoietin in the correction of anemia using Recombinant erythropoietin drugs in patients with lymphoproliferative diseases. Kazanskiy me­ditsinskiy zhurnal. 2012; 93 (4): 584–590 (In Russ.)

[34] Романенко Н.А., Беркос М.В., Бессмельцев С.С. и др. Прогностическое значение сывороточного эритропоэтина при коррекции анемии препаратами рекомбинантного эритропоэтина у пациентов с лимфопролиферативными заболеваниями. Казанский мед. ж. 2012; 93 (4): 584–590.

[35] Romanenko N.A., Bessmel’tsev S.S., Berkos M.V. et al. Prognostic valuable some of laboratory blood tests in predictive of efficacy Erythropoiesis-stimulating treatment in anemic patients with lymphoproliferative disorders. Terapevticjeskiy arkhiv. 2013; 85 (8): 81–86. (In Russ.)

[36] Романенко Н.А., Бессмельцев С.С., Беркос М.В. и др. Прогностическая значимость ряда лабораторных показателей крови при использовании препаратов, стимулирующих эритропоэз у больных лимфопролиферативными заболеваниями с анемией. Тер. архив. 2013; 85 (8): 81–86.

[37] Lyamkina A.S., Pospelova T.I., Obgol’ts Yu.N. et al. Pathogenesis and modern the­rapy of anema in elderly patients with lymphoproliferative diseases. Sibirskiy nauchnyy meditsinskiy zhurnal (Byulleten' SO RAMN). 2013; 33 (1): 54–60. (In Russ.)

[38] Лямкина А.С., Поспелова Т.И., Обгольц Ю.Н. и др. Патогенез и современная терапия анемического синдрома у пожилых больных лимфопролиферативными заболеваниями. Сибирский научн. мед. ж. (Бюлл. СО РАМН). 2013; 33 (1): 54–60.

[39] Tsopra O.A., Ziros P.G., Lagadinou E.D. et al. Di­sease-related anemia in chronic lymphocytic leukemia is not due to intrinsic defects of erythroid precursors: a pos­sible pathogenetic role for tumor necrosis factor-alpha. Acta. Haematol. 2009; 121 (4): 187–195.

[40] Wang T., Tu M.F., Zhu J. The role of cytokines in lymphoma with anemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013; 21 (2): 392–395.

[41] Chopra M., Langenhorst D., Beilhack A. et al. Interleukin-2 critically regulates bone marrow erythropoiesis and prevents anemia development. Eur. J. Immunol. 2015; 45 (12): 3362–3374. DOI: 10.1002/eji.201545596.

[42] Buck I., Morceau F., Cristofanon S. et al. The inhibitory effect of the proinflammatory cytokine TNFalpha on erythroid differentiation involves erythroid transcription factor modulation. Int. J. Oncol. 2009; 34 (3): 853–860. DOI: 10.1016/j.bcp.2008.08.025.

[43] Buck I., Morceau F., Cristofanon S. et al. Tumor necrosis factor alpha inhibits erythroid differentiation in human erythropoietin-dependent cells involving p38 MAPK pathway, GATA-1 and FOG-1 downregulation and ­GATA-2 upregulation. Biochem. Pharmacol. 2008; 76 (10): 1229–1239. DOI: 10.1016/j.bcp.2008.08.025.

[44] Sa­khin V.T., Kryukov E.V., Rukavitsyn O.A. The significance of interleukin 6 in the pathogenesis of anemia in patients with solid tumors and the possibility of therapeutic correction. Vestnik gematologii. 2019; 15 (1): 22–28. (In Russ.)

[45] Сахин В.Т., Крюков Е.В., Рукавицын О.А. Значение интерлейкина 6 в патогенезе анемии у больных с солидными опухолями и возможности терапевтической коррекции. Вестн. гематол. 2019; 15 (1): 22–28.

[46] Hohaus S., Massini G., Giachelia M. et al. Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin. J. Clin. Oncol. 2010; 28 (15): 2538–2543. DOI: 10.1200/JCO.2009.27.6873.

[47] Lee P., Peng H., Gelbart T. et al. Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc. Nat. Acad. Sci. USA. 2005; 102: 1906–1910. DOI: 10.1073/pnas.0409808102.

[48] Kim A., Rivera S., Shprung D. et al. Mouse mo­dels of anemia of cancer. PloS One. 2014; 9 (3): e93283. DOI: 10.1371/journal.pone.0093283.

[49] Nemeth E., Rivera S., Gabajan V. et al. IL-6 me­diates hyppoferremia inducting the synthesis of the iron regulatory hormone hepcidin. J. Clin. Inv. 2004; 113: 1271–1276. DOI: 10.1172/JCI200420945.

[50] Rivera S., Liu L., Nemeth E. et al. Hepcidin excess induces the sequestration of iron and exacerbates tumor-­associated anemia. Blood. 2005; 105 (4): 1797–1802. DOI: 10.1182/blood-2004-08-3375.

[51] Ukarma L., Johannes H., Beyer U. et al. Hepcidin as a predictor of response to epoetin therapy in anemic cancer patients. Clin. Chem. 2009; 55 (7): 1354–1360. DOI: 10.1373/clinchem.2008.121285.

[52] Tsvetaeva N.V., Levina A.A., Mamukova U.I. The basis of regulation of iron metabolism. Klini­cheskaya onkogematologiya. 2010; 3 (3): 278–283. (In Russ.)

[53] Цветаева Н.В., Левина А.А., Мамукова Ю.И. Основы регуляции обмена железа. Клин. онкогематол. 2010; 3 (3): 278–283.

[54] Napier I., Ponka P., Richardson D.R. Iron traffi­cking in the mitochondrion: novel pathways revealed by di­sease. Blood. 2005; 105 (5): 1867–1874. DOI: 10.1182/blood-2004-10-3856.

[55] Camaschella C. Iron and hepcidin: a story of recycling and balance. ASH Education Program Book. 2013; 2013 (1): 1–8. DOI: 10.1182/asheducation-2013.1.1.

[56] Park C.H., Valore E.V., Waring A.J., Ganz T. Hepcidin: a urinary antibacterial peptide synthesized in the li­ver. J. Biol. Chem. 2001; 276: 7806–7810. DOI: 10.1074/jbc.M008922200.

[57] Song S.N., Tomosugi N., Kawabata H. et al. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizu­mab) improves anemia of inflammation in multicentric Castleman disease. Blood. 2010; 116 (18): 3627–3634. DOI: 10.1182/blood-2010-03-271791.

[58] Fleming R.E., Sly W.S. Hepcidin: a putative iron-regulatory hormone relevant to hereditary hemochromatosis and the anemia of chronic disease. Proceed. Nat. Acad. Sci. 2001; 98 (15): 8160–8162. DOI: 10.1073/pnas.161296298.

[59] Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011; 117 (17); 4425–4433. DOI: 10.1182/blood-2011-01-258467.

[60] Hunter H.N., Fulton D.B., Ganz T., Vogel H.J. The solution structure of human hepcidin, a peptide hormone with antimicrobial activity that is involved in iron uptake and hereditary hemochromatosis. J. Biol. Chem. 2002; 277 (40): 37 597–37 603. DOI: 10.1074/jbc.M205305200.

[61] Bohlius J., Bohlke K., Castelli R. et al. Management of cancer-associated anemia with erythropoiesis-stimula­ting agents: ASCO/ASH clinical practice guideline update. Blood Adv. 2019; 3 (8): 1197–1210. DOI: 10.1182/bloodadvances.2018030387.

[62] Calleja J.L., Delgado S., del Val A. et al. Ferric carboxymaltose reduces transfusions and hospital stay in patients with colon cancer and anemia. Int. J. Colorectal Dis. 2016; 31 (3): 543–551. DOI: 10.1007/s00384-015-2461-x.

[63] Cella D., Kallich J., McDermott A., Xu X. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann. Oncol. 2004; 15 (6): 979–986. DOI: 10.1093/annonc/mdh235.

[64] Keeler B.D., Simpson J.A., Ng S. et al. The feasibility and clinical efficacy of intravenous iron administration for preoperative anaemia in patients with colorectal cancer. Color. Dis. 2014; 16 (10): 794–800. DOI: 10.1111/codi.12683.

[65] Lebrun F., Klastersky J., Levacq D. et al. Intravenous iron therapy for anemic cancer patients: a review of recently published clinical studies. Support Care Cancer. 2017; 25 (7): 2313–2319. DOI: 10.1007/s00520-017-3672-1.

[66] Romanenko N., Slascheva I., Golovchenko R., Abdulkadyrov K. Study of effectiveness recombinant human erythropoietin and quality of life in lymphoproliferative disor­ders patients with anemia. Haematologica. 2011; 96 (2): 748.

RIGHTS & PERMISSIONS

Romanenko N.A., Bessmeltsev S.S., Alborov A.E., Shilova E.R., Chechetkin A.V., Khanevich M.D.